Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia - Full Text View -...
This phase I/II trial studies the side effects and best dose of vorinostat and azacitidine and to see how well they work in ... Patients receive azacitidine subcutaneously (SC) once daily (QD) on days 1-7 and vorinostat orally (PO) 2-3 times daily on days ... I. To evaluate the safety and toxicity of vorinostat in combination with azacitidine in patients with myelodysplastic syndromes ... Drug: Azacitidine Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: Vorinostat Phase 1 Phase 2 ...https://clinicaltrials.gov/ct2/show/NCT00392353
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural...
This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating ... Patients receive azacitidine subcutaneously (SC) on days 1-10 and vorinostat orally (PO) twice daily (BID) on days 1-14. ... I. Define toxicity profile of escalating doses of suberoylanilide hydroxamic acid (SAHA) given in conjunction with a fixed dose ... Experimental: Treatment (azacitidine, vorinostat) Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1- ...https://clinicaltrials.gov/ct2/show/NCT00336063?term=nasopharyngeal+cancer&cond=%22Nasopharyngeal+Carcinoma%22&rank=12
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
... azacitidine in treating patients with myelodysplastic syndromes or ac ... This phase I/II trial is studying the side effects and best dose of vorinostat and ... phase II study.. PHASE I: Patients receive azacitidine subcutaneously (SC) once daily on days 1-7 and. vorinostat (SAHA) orally ... in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS). Trial Phase:. Phase 1/Phase 2. Minimum Age ...http://www.knowcancer.com/cancer-trials/NCT00392353/
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or...
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating ... ARM I: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 or days 1-5 and 8-9, and lenalidomide ... Toxicity Rate [ Time Frame: Up to 5 years ]. Adverse events that are possibly, probably or definitely related to study drug are ... Experimental: Arm III (azacitidine and vorinostat) Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. ...https://clinicaltrials.gov/ct2/show/record/NCT01522976?term=NCT01522976&rank=1
Bruno C Medeiros, MD | Stanford Medicine Profiles
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating ... Vorinostat (400 mg/day orally from Days 1-9), azacitidine (75 mg/m(2)/day intravenously or subcutaneously from Days 1-7), and ... for toxicity. Patients will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to ... This randomized phase II trial studies azacitidine with or without entinostat to see how well they work compared to azacitidine ...https://med.stanford.edu/profiles/bruno-medeiros?tab=research-and-scholarship
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML - Full Text View -...
Dose-limiting Toxicity and Maximum Tolerated Dose of Vorinostat (Phase I) [ Time Frame: 42 days ]. *Efficacy Defined as Best ... Patients receive vorinostat orally (PO) on days 1-9, azacitidine subcutaneously (SC) or intravenously (IV) over 10-40 minutes ... NCI-2012-01147 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ). IR-6921 ( Other Identifier: Fred Hutchinson ... Experimental: Phase 2 - Treatment at Selected Dose Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, ...https://clinicaltrials.gov/ct2/show/NCT00895934?cond=%22Acute+myelomonocytic+leukemia%22&rank=15
Steven Coutre | Stanford Medicine Profiles
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia BLOOD Nand, S., ... observed toxicity. Bortezomib will be administered either intravenously or sub-cutaneously, twice a week on days 1 and 4, two ... Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Not Recruiting The ... A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood Nand, S ...https://med.stanford.edu/profiles/steven-coutre
December | 2012 | Phosphorylase Inhibitors
A phase II examine of vorinostat in mixture with idarubicin and cytarabine as front line treatment for AML or MDS clients was ... NCT01016600, opening in January 2010, Plastid is definitely an open label trial wanting at lenalidomide azacitidine in relapsed ... Clofarabine plus lower dose cytarabine accomplished high response costs with Survivin a manageable toxicity profile and reduced ... reprogrammed cells generated secure homogenous hyaline cartilage like tissue with out tumor formation when subcutaneously ...http://phosphorylaseinhibitors.com/2012/12
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML - Full...
Drug Information available for: Azacitidine Fludarabine Fludarabine phosphate Genetic and Rare Diseases Information Center ... The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at ... This regimen is very similar to the chemotherapy regimen proposed for the next relapsed AML trial within the Children's ... Patients who relapsed while they are receiving cytotoxic therapy (including AZA , decitabine, or vorinostat) At least 14 days ...https://clinicaltrials.gov/ct2/show/study/NCT01861002
Further work with entinostat is under way in preparation for an early-phase clinical trial. ... Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small ... TXNIP-transduced or vector cells were injected subcutaneously into female, athymic, nude mice. The same number of cells with ... vorinostat, in combination with mTOR inhibitors synergistically killed malignant peripheral nerve sheath tumors and KRAS-mutant ...http://mct.aacrjournals.org/content/17/9/2013
US Patent # 9,987,258. Histone deacetylase as a modulator of PDL1 expression and activity - Patents.com
... including the ongoing Phase 2 Multiple Myeloma clinical trial using the HDAC6inh ACY1215, which has shown important anti-tumor ... 13A shows in vivo tumor growth of C57BL/6 mice injected subcutaneously with B16 WT cells. Mice were either untreated or treated ... Non-limiting examples of class I HDAC inhibitors include Vorinostat, LBH589, ITF2357, PXD-101, Depsipeptide, MS-275, and ... without lethal toxicity, and preferably causing no more than an acceptable level of side effects or morbidity. One skilled in ...http://patents.com/us-9987258.html
Susan Knox, MD, PhD | Stanford Medicine Profiles
... without neurologic or systemic toxicity in the context of a phase I/II clinical trial. RRx-001 is an reactive oxygen and ... Similar results were obtained with KGF administered subcutaneously. Treatment with both KGF and stem cell factor (previously ... entinostat and vorinostat), DNA hypomethylating agents such as the DNMTIs (decitabine (DEC), 5-azacytidine (5-AZA)) and redox ... striking safety profile of RRx-001 in comparison to other more toxic epigenetic and immunomodulatory agents such as azacitidine ...https://med.stanford.edu/profiles/susan-knox
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Patent application
0177] LPA contributes to both the early phase (barrier dysfunction and monocyte adhesion of the endothelium) and the late phase ... Clinical Trial in Humans with Idiopathic Pulmonary Fibrosis (IPF) Purpose  The purposes of this study is to assess the ... 0379] Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in ... In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or ...http://www.patentsencyclopedia.com/app/20120258987
US Patent # 9,987,369. Vitamin functionalized gel-forming block copolymers for biomedical applications - Patents.com
During the early phase of treatment, the anti-tumor efficacy of the subcutaneously injected herceptin-loaded hydrogel Example ... Recently, F Hoffmann-La Roche reported a phase 3 clinical trial (HannaH study) involving the subcutaneous (versus intravenous) ... increasing toxicity to microbes) and/or increasing HC50 values (lowering toxicity to mammalian red blood cells) when 25% to 100 ... Vorinostat), and ZOMETA.RTM. (Zoledronic acid). Also disclosed is an antimicrobial composition for killing a microbe. The ...http://patents.com/us-9987369.html